Tech Company Financing Transactions
Asklepios BioPharmaceutical Funding Round
On 4/12/2019, Asklepios BioPharmaceutical announced $235 million in investment from TPG Capital and Vida Ventures.
Transaction Overview
Company Name
Announced On
4/12/2019
Transaction Type
Venture Equity
Amount
$235,000,000
Round
Undisclosed
Investors
TPG Capital (John Schilling)
Vida Ventures (Fred Cohen)
Proceeds Purpose
The investment provides AskBio with additional capital to help advance and expand clinical trials, enhance its manufacturing capabilities and capacity, and drive long-term growth.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
20 T.W. Alexander 110
Research Triangle Park, NC 27709
USA
Research Triangle Park, NC 27709
USA
Phone
Website
Email Address
Overview
Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held AAV gene therapy based company founded in 2001 to advance the work of Dr. Richard Jude Samulski, former Director of the Gene Therapy Center at the University of North Carolina (UNC) from the lab into the clinic. Dr. Samulski was the first to clone AAV for therapeutic purposes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sheila Mikhail
Chief Medical Officer
Martin Childers
Chief Operating Officer
Robert King
Chief Scientific Officer
Philippe Moullier
Chief Technical Officer
Josh Grieger
Co-Founder
Richard Samulski
VP - Regulatory Affairs
Diane Balderson
Browse more venture capital transactions:
Prev: 4/12/2019: Flexa venture capital transaction
Next: 4/12/2019: Lemonade venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs